# Study Evaluating the Efficacy of a Reduced Dose Atazanavir in HIV-1-infected Patients

> **NCT02473328** · PHASE2 · COMPLETED · sponsor: **Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida** · enrollment: 90 (actual)

## Conditions studied

- HIV-1 Infection

## Interventions

- **DRUG:** Atazanavir 200 mg/r

## Key facts

- **NCT ID:** NCT02473328
- **Lead sponsor:** Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06
- **Primary completion:** 2017-12
- **Final completion:** 2017-12
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2018-08-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02473328

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02473328, "Study Evaluating the Efficacy of a Reduced Dose Atazanavir in HIV-1-infected Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02473328. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*